H.C. Wainwright analyst Oren Livnat lowered the firm’s price target on Pacira to $63 from $68 and keeps a Buy rating on the shares post the Q2 results. The company reported slower procedure recovery, but there is “growth from here,” the analyst tells investors in a research note. The firm says the stock is at historically low multiples despite “ample” free cash flow and long runway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCRX: